Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.45 |
| ▸ | TTPA | P49638 | 3/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140309 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL29670772 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6362676 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL22899966 | 0.90 | PTGS1 (0.70) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15851247 | 0.90 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL31326006 | 0.87 | PTGS1 (0.65) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL30951067 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2393197 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL21344343 | 0.86 | PTGS1 (0.52) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL7895023 | 0.86 | PTGS1 (0.91) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126011-A | Method for chiral resolution of Trolox and Trolox ester compound enantiomer | 辽宁大学 | 2024-06-04 | — | — | CN | claimed |
| US-7615650-B2 | Process for producing chroman compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-11-10 | — | — | US | claimed |
| US-20070179304-A1 | Process for producing chroman compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2007-08-02 | — | — | US | claimed |
| EP-1710239-A1 | PROCESS FOR PRODUCING CHROMAN COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-10-11 | — | — | EP | claimed |
| EP-0445735-A1 | Melanogenesis-inhibiting endermic preparation | Sansho Seiyaku Co., Ltd. (JP) | 1991-09-11 | — | — | EP | claimed |
| US-20240400529-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240368098-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240293339-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA | Stealth Bio Therapeutics Inc. (US) | 2024-09-05 | — | — | US | disclosed |
| US-12049455-B2 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-118126011-A | Method for chiral resolution of Trolox and Trolox ester compound enantiomer | 辽宁大学 | 2024-06-04 | — | — | CN | disclosed |
| US-20230330060-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SULFATEQ B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230330060-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SULFATEQ B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-4205001-A | Inversion process | HOFFMANN-LA ROCHE INC. (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003221-A2 | Process for the manufacture of 3,4-dihydro-benzopyran derivatives and starting materials in this process | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-08-08 | — | — | EP | disclosed |
| US-4150050-A | 3,6-Dioxo-1,4-cyclohexadien-1-yl-butandate esters | HOFFMANN-LA ROCHE INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4026907-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-4018799-A | INTERMEDIATES FOR TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4003919-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3986980-A | SYNERGISTIC ANTIOXIDANT COMPOSITION COMPRISING ASCORBIC ACID AND 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2- CARBOXYLIC ACID | HOFFMANN-LA ROCHE INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3947473-A | (6-HYDROXY-CHROMAN-2-YL) CARBOXYLIC ACID DERIVATIVES | HOFFMAN-LA ROCHE INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293339-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA | AIFM2, FH, FECH | PTGS1 332/4885PTGS2 455/4885CYP1A2 4395/4885 |
| US-20070179304-A1 | Process for producing chroman compound | TAF9, TAF1, CHD1 | PTGS1 509/4885PTGS2 1158/4885CYP1A2 71/4885 |
| US-20240400529-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | FH, COQ8A, TFAM | PTGS1 682/4885PTGS2 1030/4885CYP1A2 2185/4885 |
| US-12049455-B2 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | FH, COQ8A, TFAM | PTGS1 682/4885PTGS2 1030/4885CYP1A2 2185/4885 |
| US-20230330060-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SQOR, SDHA, NDUFV2 | PTGS1 550/4885PTGS2 454/4885CYP1A2 226/4885 |
| US-20240368098-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | FH, COQ8A, TFAM | PTGS1 682/4885PTGS2 1030/4885CYP1A2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.